AU2014210260B2 - Bicyclic pyrimidone compounds as inhibitors of Lp-PLA2 - Google Patents

Bicyclic pyrimidone compounds as inhibitors of Lp-PLA2 Download PDF

Info

Publication number
AU2014210260B2
AU2014210260B2 AU2014210260A AU2014210260A AU2014210260B2 AU 2014210260 B2 AU2014210260 B2 AU 2014210260B2 AU 2014210260 A AU2014210260 A AU 2014210260A AU 2014210260 A AU2014210260 A AU 2014210260A AU 2014210260 B2 AU2014210260 B2 AU 2014210260B2
Authority
AU
Australia
Prior art keywords
pyrimidin
pyrimido
dihydro
title compound
esi
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2014210260A
Other languages
English (en)
Other versions
AU2014210260A1 (en
Inventor
Zehong Wan
Xiaomin Zhang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GlaxoSmithKline Intellectual Property Development Ltd
Original Assignee
GlaxoSmithKline Intellectual Property Development Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GlaxoSmithKline Intellectual Property Development Ltd filed Critical GlaxoSmithKline Intellectual Property Development Ltd
Publication of AU2014210260A1 publication Critical patent/AU2014210260A1/en
Application granted granted Critical
Publication of AU2014210260B2 publication Critical patent/AU2014210260B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Epidemiology (AREA)
AU2014210260A 2013-01-25 2014-01-23 Bicyclic pyrimidone compounds as inhibitors of Lp-PLA2 Ceased AU2014210260B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CNPCT/CN2013/070977 2013-01-25
CN2013070977 2013-01-25
PCT/CN2014/071206 WO2014114249A1 (en) 2013-01-25 2014-01-23 Bicyclic pyrimidone compounds as inhibitors of lp-pla2

Publications (2)

Publication Number Publication Date
AU2014210260A1 AU2014210260A1 (en) 2015-07-30
AU2014210260B2 true AU2014210260B2 (en) 2016-08-04

Family

ID=51226939

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2014210260A Ceased AU2014210260B2 (en) 2013-01-25 2014-01-23 Bicyclic pyrimidone compounds as inhibitors of Lp-PLA2

Country Status (9)

Country Link
US (1) US20150344485A1 (enExample)
EP (1) EP2948456A4 (enExample)
JP (1) JP2016505053A (enExample)
KR (1) KR20150108896A (enExample)
AU (1) AU2014210260B2 (enExample)
BR (1) BR112015017397A2 (enExample)
CA (1) CA2899143A1 (enExample)
RU (1) RU2015135824A (enExample)
WO (1) WO2014114249A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20170034889A (ko) 2014-07-22 2017-03-29 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 화합물
CN105777653A (zh) * 2014-12-26 2016-07-20 中国科学院上海药物研究所 用作Lp-PLA2抑制剂的嘧啶酮类化合物及其药物组合物
CN106188063A (zh) * 2015-05-08 2016-12-07 中国科学院上海药物研究所 用作Lp-PLA2抑制剂的双环类化合物、其制备方法及医药用途
CN105001098B (zh) * 2015-07-26 2016-09-14 嵊州市油脂化工有限公司 一种3(r)/(s)-氨基-1-丁醇的制备方法
SG11202012131VA (en) 2018-06-08 2021-01-28 Attabotics Inc Improved storage and retrieval systems
CN110683960A (zh) * 2019-08-22 2020-01-14 台州达辰药业有限公司 一种（r）-3-氨基丁醇的合成方法
CN112574221B (zh) * 2019-09-30 2022-03-04 上海纽思克生物科技有限公司 四环嘧啶酮类化合物、其制备方法、其组合物和用途

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003087088A2 (en) * 2002-04-10 2003-10-23 Glaxo Group Limited (condensed) pyrimidone and (condensed) pyridone compounds, processes for their preparation, and pharmaceutical compositions containing them
WO2008048867A2 (en) * 2006-10-13 2008-04-24 Glaxo Group Limited Bicyclic heteroaromatic compounds
WO2013014185A1 (en) * 2011-07-27 2013-01-31 Glaxo Group Limited Bicyclic pyrimidone compounds

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9421816D0 (en) 1994-10-29 1994-12-14 Smithkline Beecham Plc Novel compounds
WO1996019451A1 (en) 1994-12-22 1996-06-27 Smithkline Beecham Plc Substituted azetidin-2-ones for treatment of atherosclerosis
CH690264A5 (fr) 1995-06-30 2000-06-30 Symphar Sa Dérivés aminophosphonates substitués, leur procédé de préparation et leur utilisation pour la préparation de compositions pharmaceutiques.
WO1997002242A1 (en) 1995-07-01 1997-01-23 Smithkline Beecham Plc Azetidinone derivatives for the treatment of atherosclerosis
JP2002515728A (ja) 1995-09-29 2002-05-28 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー 新規用途
JP2000502079A (ja) 1995-12-08 2000-02-22 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー アテローム性動脈硬化症の治療のための単環β―ラクタム誘導体
EP0865429A1 (en) 1995-12-08 1998-09-23 Smithkline Beecham Plc Azetidinone compounds for the treatment of atherosclerosis
GB9608649D0 (en) 1996-04-26 1996-07-03 Smithkline Beecham Plc Novel compounds
CZ341098A3 (cs) 1996-04-26 1999-03-17 Smithkline Beecham Plc Azetidinonové deriváty pro ošetřování aterosklerózy
GB9626536D0 (en) 1996-12-20 1997-02-05 Symphar Sa Novel compounds
GB9626616D0 (en) 1996-12-20 1997-02-05 Symphar Sa Novel compounds
GB9626615D0 (en) 1996-12-20 1997-02-05 Symphar Sa Novel compounds
EP1028955B1 (en) 1997-11-06 2003-07-16 SmithKline Beecham plc Pyrimidinone compounds and pharmaceutical compositions containing them
DE69911980T2 (de) 1998-08-21 2004-09-09 Smithkline Beecham P.L.C., Brentford Pyrimidinonderivate zur behandlung von atheroscleros
GB9910079D0 (en) 1999-05-01 1999-06-30 Smithkline Beecham Plc Novel compounds
ATE432265T1 (de) 1999-05-01 2009-06-15 Smithkline Beecham Plc Pyrimidinon verbindungen
GB9910378D0 (en) 1999-05-05 1999-06-30 Smithkline Beecham Plc Novel compounds
JP3757703B2 (ja) 1999-09-22 2006-03-22 凸版印刷株式会社 再封可能な開口維持部材付パウチ
NZ520752A (en) 2000-02-16 2004-03-26 Smithkline Beecham P Pyrimidine-4-one derivatives as LDL-PLA2 inhibitors
GB0024808D0 (en) 2000-10-10 2000-11-22 Smithkline Beecham Plc Novel compounds
GB0024807D0 (en) 2000-10-10 2000-11-22 Smithkline Beecham Plc Novel compounds
GB0119793D0 (en) 2001-08-14 2001-10-03 Smithkline Beecham Plc Novel compounds
GB0119795D0 (en) 2001-08-14 2001-10-03 Smithkline Beecham Plc Novel process
GB0127139D0 (en) 2001-11-10 2002-01-02 Smithkline Beecham Novel compounds
GB0127143D0 (en) 2001-11-10 2002-01-02 Smithkline Beecham Novel compounds
GB0127140D0 (en) 2001-11-10 2002-01-02 Smithkline Beecham Novel compounds
GB0127141D0 (en) 2001-11-10 2002-01-02 Smithkline Beecham Plc Novel compounds
GB0208279D0 (en) 2002-04-10 2002-05-22 Glaxo Group Ltd Novel compounds
EP1644353A1 (de) 2003-07-02 2006-04-12 Bayer HealthCare AG Amid-substituierte 1, 2, 4-triazin-5 (2h) - one zur behandlung von chronisch inflammatorischen krankheiten
DE102004061008A1 (de) 2004-12-18 2006-06-22 Bayer Healthcare Ag 3-Arylalkyl- und 3-Heteroarylalkyl-substituierte 1,2,4-Triazin-5(2H)-one
DE102004061009A1 (de) 2004-12-18 2006-06-22 Bayer Healthcare Ag Substituierte 1,2,4-Triazin-5(2H)-one
US20080090852A1 (en) 2006-10-13 2008-04-17 Colin Andrew Leach Bicyclic Heteroaromatic Compounds
US20080090851A1 (en) 2006-10-13 2008-04-17 Colin Andrew Leach Bicyclic Heteroaromatic Compounds
US7705005B2 (en) 2006-10-13 2010-04-27 Glaxo Group Limited Bicyclic heteroaromatic compounds
US20080279846A1 (en) 2007-05-11 2008-11-13 Thomas Jefferson University Methods of treatment and prevention of neurodegenerative diseases and disorders
CA2687079A1 (en) 2007-05-11 2008-11-20 The Trustees Of The University Of Pennsylvania Methods of treatment of skin ulcers
US8962633B2 (en) 2007-05-11 2015-02-24 Thomas Jefferson University Methods of treatment and prevention of metabolic bone diseases and disorders
JP2011088847A (ja) * 2009-10-21 2011-05-06 Takeda Chem Ind Ltd 三環性化合物およびその用途
JP2013537203A (ja) * 2010-09-20 2013-09-30 グラクソ グループ リミテッド 三環式化合物、製造方法、およびそれらの使用
WO2012075917A1 (en) * 2010-12-06 2012-06-14 Glaxo Group Limited Compounds
EP2651403B1 (en) 2010-12-17 2020-12-02 Glaxo Group Limited Use of lp-pla2 inhibitors in the treatment and prevention of eye diseases

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003087088A2 (en) * 2002-04-10 2003-10-23 Glaxo Group Limited (condensed) pyrimidone and (condensed) pyridone compounds, processes for their preparation, and pharmaceutical compositions containing them
WO2008048867A2 (en) * 2006-10-13 2008-04-24 Glaxo Group Limited Bicyclic heteroaromatic compounds
WO2013014185A1 (en) * 2011-07-27 2013-01-31 Glaxo Group Limited Bicyclic pyrimidone compounds

Also Published As

Publication number Publication date
KR20150108896A (ko) 2015-09-30
CA2899143A1 (en) 2014-07-31
RU2015135824A (ru) 2017-03-03
BR112015017397A2 (pt) 2017-07-11
AU2014210260A1 (en) 2015-07-30
WO2014114249A1 (en) 2014-07-31
JP2016505053A (ja) 2016-02-18
US20150344485A1 (en) 2015-12-03
EP2948456A4 (en) 2016-09-14
EP2948456A1 (en) 2015-12-02

Similar Documents

Publication Publication Date Title
AU2012288865B2 (en) Bicyclic pyrimidone compounds
AU2014209949B2 (en) 2,3-dihydroimidazol(1,2-c)pyrimidin-5(1h)-one based lipoprotein-associated phospholipase a2 (Lp-PLA2) inhibitors
AU2014210260B2 (en) Bicyclic pyrimidone compounds as inhibitors of Lp-PLA2
AU2015292049B2 (en) Compounds
US8975400B2 (en) 2,3-dihydroimidazo[1, 2-c] pyrimidin-5(1 H)-one compounds use as LP-PLA2 inhibitors
CN104968665A (zh) 作为lp-pla2抑制剂的双环嘧啶酮化合物
AU2014210259B2 (en) Compounds
US9051325B2 (en) Bicyclic [5,6] imidazo pyrimodone compounds for use in the treatment of diseases or conditions mediated by Lp-PLA2

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired